Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 673 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 673 shares of Medpace stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $620.38, for a total transaction of $417,515.74. Following the transaction, the chief executive officer owned 544,544 shares in the company, valued at $337,824,206.72. The trade was a 0.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Medpace Price Performance

NASDAQ MEDP traded down $7.48 during trading hours on Thursday, hitting $611.57. The company had a trading volume of 198,148 shares, compared to its average volume of 344,156. The firm’s 50 day moving average is $559.49 and its 200 day moving average is $493.31. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The company has a market capitalization of $17.07 billion, a price-to-earnings ratio of 35.85, a P/E/G ratio of 2.74 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the firm posted $3.10 earnings per share. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of several recent research reports. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and increased their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Robert W. Baird lifted their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. Mizuho boosted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, TD Cowen upped their price objective on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $584.18.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System grew its holdings in Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after acquiring an additional 13,963,607 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Medpace in the 2nd quarter valued at about $1,323,047,000. AQR Capital Management LLC lifted its position in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Madison Asset Management LLC acquired a new position in Medpace in the second quarter worth about $128,956,000. Finally, Bank of America Corp DE acquired a new position in Medpace in the second quarter worth about $116,891,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.